Am J Clin Oncol

1. AKRAM U, Nadeem ZA, Rehman OU, Raza MA, et al
   Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
   Am J Clin Oncol. 2026 Jan 26. doi: 10.1097/COC.0000000000001299.
   

   >> Share

   
   

   
   Am J Pathol

2. FILGES S, Jonasson E, Arrabal MDCL, Andersson L, et al
   Single-cell triomics analysis of tumor cells infiltrating patient-derived breast cancer scaffolds.
   Am J Pathol. 2026 Jan 22:S0002-9440(26)00008.
   

   >> Share

   
   
3. ZHU R, Jiang G, Shen J, Gong C, et al
   Deciphering the cellular and metabolic landscape of lymph node metastasis in breast cancer using single-cell and spatial multi-omics.
   Am J Pathol. 2026 Jan 22:S0002-9440(26)00007.
   

   >> Share

   
   

   
   Ann Surg Oncol

4. BEERTHUIZEN AWJ, Snellen TIM, Bartels SA, Kuijer A, et al
   ASO Visual Abstract: The Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981-22023 AMAROS Trial.
   Ann Surg Oncol. 2026 Jan 24. doi: 10.1245/s10434-025-19063.
   

   >> Share

   
   
5. KO G, Li Q, Liu N, Amir E, et al
   Breast Cancer Surgery Wait Times and COVID-19: A Canadian Population-Based Analysis.
   Ann Surg Oncol. 2026 Jan 25. doi: 10.1245/s10434-025-19029.
   

   >> Share

   
   
6. ELAM M, Hillas J, Moyal-Smith R, Padamsee TJ, et al
   Bridging Operative Standards to Clinical Practice: A Case Comparison of Synoptic Operative Report Implementation in Breast Cancer Surgery.
   Ann Surg Oncol. 2026 Jan 27. doi: 10.1245/s10434-025-19042.
   

   >> Share

   
   

   
   BMC Cancer

7. WOOF VG, Howell A, Fox L, McWilliams L, et al
   How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK family history risk and prevention clinic.
   BMC Cancer. 2026 Jan 29. doi: 10.1186/s12885-026-15651.
   

   >> Share

   
   
8. SAFAVI A, Mohammadzadeh N, Kaviani A, Dadashi A, et al
   Axillary staging in post-neoadjuvant chemotherapy breast cancer patients: prognostic analysis and validation of axillary nodal metrics and comparison of pathological node staging versus the lymph node ratio systems in a 169-case series.
   BMC Cancer. 2026 Jan 30. doi: 10.1186/s12885-026-15564.
   

   >> Share

   
   

   
   Breast Cancer

9. SCHERER C, Fung V, Anzellini D, Osti MF, et al
   Real world experience of intraoperative radiation therapy (IORT) during lumpectomy for early-stage breast cancer: retrospective data from a single large institutional observational study.
   Breast Cancer. 2026 Jan 24. doi: 10.1007/s12282-026-01824.
   

   >> Share

   
   
10. NAGAI SE, Hattori M, Yoshinami T, Masuda H, et al
    Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
    Breast Cancer. 2026 Jan 27. doi: 10.1007/s12282-025-01787.
    

    >> Share

    
    

    
    Breast Cancer (Auckl)

11. KHEIR O, Baatiah N, Alotaibi A, Dossary S, et al
    Perceptions of Breast Cancer: A Cross-Sectional Study Using the Breast Cancer Perception Scale (BPS).
    Breast Cancer (Auckl). 2026;20:11782234251410402.
    

    >> Share

    
    

    
    Breast Cancer Res

12. BORGEL A, Camenen E, Miquel C, Bertheau P, et al
    Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors.
    Breast Cancer Res. 2025;28:26.
    

    >> Share

    
    
13. RAJAN KK, Nijveldt JJ, Helthuis JHG, Roeloffzen EMA, et al
    Diagnostic accuracy of FDG-PET-CT to predict axillary lymph node response after neo-adjuvant chemotherapy in lymph node-positive breast cancer patients.
    Breast Cancer Res. 2026 Jan 23. doi: 10.1186/s13058-026-02223.
    

    >> Share

    
    
14. COHEN EN, Gao H, Tin S, Wu Q, et al
    High levels of circulating miR-19a-3p in patients with metastatic HER2 + breast cancer are associated with a favorable prognosis and anti-tumor immune responses.
    Breast Cancer Res. 2026;28:3.
    

    >> Share

    
    
15. FANG Y, Guo C, Zheng F, Xiao Y, et al
    HSP90AA1-VDAC1 interaction contributes to breast cancer progression and doxorubicin resistance through PI3K/AKT signaling.
    Breast Cancer Res. 2026 Jan 27. doi: 10.1186/s13058-026-02225.
    

    >> Share

    
    
16. YU CC, Hsieh CC, Huang YT, Chu CH, et al
    Toxicity profiles of proton and photon radiotherapy in postoperative breast cancer: a 10-year real-world cohort study.
    Breast Cancer Res. 2026 Jan 27. doi: 10.1186/s13058-026-02227.
    

    >> Share

    
    
17. BOOMSTRA E, de Ligt KM, Tissier R, Clouth F, et al
    One size does not fit all: data-driven insights of patient-reported outcomes to tailor supportive care in breast cancer.
    Breast Cancer Res. 2026 Jan 30. doi: 10.1186/s13058-026-02228.
    

    >> Share

    
    
18. YANG L, Chen Z, Chen Y, Yang J, et al
    Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer.
    Breast Cancer Res. 2026 Jan 29. doi: 10.1186/s13058-026-02230.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

19. RICCERI F, Favaro E, Catalano A, Gilcrease GW, et al
    Risk of myocardial infarction and stroke after breast cancer: an analysis of a population of 1.3 million women from North-West Italy.
    Breast Cancer Res Treat. 2026;215:66.
    

    >> Share

    
    
20. LEGGAT-BARR K, Lewis T, Tice JA, Tsopurashvili E, et al
    Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.
    Breast Cancer Res Treat. 2026;215:65.
    

    >> Share

    
    
21. LAMMERS EMJ, Beens-van Dijk J, Nijdam A, Menezes R, et al
    Dual-modality breast cancer screening compared to MRI or mammography alone among female Hodgkin lymphoma survivors who received chest radiotherapy.
    Breast Cancer Res Treat. 2026;215:64.
    

    >> Share

    
    
22. LAVIGNE O, Poumeaud F, Reverdy T, Huynh VT, et al
    Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study.
    Breast Cancer Res Treat. 2026;215:63.
    

    >> Share

    
    
23. FUMAROLA C, Caffarra C, La Monica S, Galetti M, et al
    Correction: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
    Breast Cancer Res Treat. 2026;215:62.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

24. JI X, Yang Y, Ma C, Huang W, et al
    Recent advances in bispecific antibody-drug conjugates for breast cancer therapy.
    Cancer Chemother Pharmacol. 2026;96:15.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

25. VIDAL GA, Katz J, Sadetsky N, Dabrowski EC, et al
    Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women With HR+/HER2- Metastatic Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    

    
    Clin Breast Cancer

26. NORI CUCCHIARI J, Di Naro F, Migliaro G, Baldi Giorgi SE, et al
    Cryoablation for Treatment of Early-Stage Breast Cancer: Efficacy and Quality of Life Assessment.
    Clin Breast Cancer. 2025;26:70-79.
    

    >> Share

    
    
27. DUONG A, Fritzsche D, Indorf AL
    Practical Considerations for the Use of Antiemetics in Pregnant Patients With Breast Cancer.
    Clin Breast Cancer. 2026;26:80-86.
    

    >> Share

    
    
28. HUANG S, Xi Y, Gao J, Yu S, et al
    LINC00511 Promotes Breast Cancer Cell Proliferation and Invasion by Mediating MYC-Mediated Regulation of VASP.
    Clin Breast Cancer. 2026 Jan 5:S1526-8209(25)00356.
    

    >> Share

    
    

    
    Clin Cancer Res

29. BIANCHINI G, Malorni L, Caputo R, Zambelli A, et al
    Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial.
    Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-0650.
    

    >> Share

    
    
30. RAMPA DR, Seo M, Ogata N, Yang Z, et al
    Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.
    Clin Cancer Res. 2026 Jan 27. doi: 10.1158/1078-0432.CCR-25-3321.
    

    >> Share

    
    

    
    Int J Cancer

31. FINK H, Morgan E, Bardot A, Jurado D, et al
    Breast cancer survival by stage at diagnosis in countries in transition: A population-based study.
    Int J Cancer. 2026 Jan 27. doi: 10.1002/ijc.70353.
    

    >> Share

    
    
32. MOHAMMED S, Galukande M, Naamala A, Parham G, et al
    Longitudinal changes in health-related quality of life after a breast cancer diagnosis in sub-Saharan Africa: Evidence from the prospective ABC-DO cohort.
    Int J Cancer. 2026 Jan 29. doi: 10.1002/ijc.70350.
    

    >> Share

    
    

    
    J Clin Oncol

33. TUNG NM, Robson ME, Li T, Nanda R, et al
    TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.
    J Clin Oncol. 2026 Jan 28:JCO2502075. doi: 10.1200/JCO-25-02075.
    

    >> Share

    
    

    
    J Natl Cancer Inst

34. PIMENTEL-PARRA GA, Soto-Ruiz N, Escalada-Hernandez P, San Martin-Rodriguez L, et al
    EHealth intervention for quality of life in long-term breast cancer survivors: Randomized controlled trial.
    J Natl Cancer Inst. 2026 Jan 24:djag020. doi: 10.1093.
    

    >> Share

    
    

    
    J Nucl Med

35. NIJVELDT JJ, Af Buren S, Tran TA, Jussing E, et al
    Feasibility of [(89)Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer.
    J Nucl Med. 2026 Jan 29:jnumed.125.271459. doi: 10.2967/jnumed.125.271459.
    

    >> Share

    
    

    
    J Pathol

36. LI B, Zhong Y, Xing Z, Zhou J, et al
    Hierarchical image pyramid transformer framework for automated breast cancer molecular subtyping using tissue microarrays.
    J Pathol. 2026 Jan 26. doi: 10.1002/path.70028.
    

    >> Share

    
    

    
    Mod Pathol

37. KWAKKENBOS K, Van Bockstal MR, Shaaban AM, Brogi E, et al
    A Worldwide Survey on Pathological Measurement of Residual Breast Cancer After Neoadjuvant Therapy: Different Interpretations of the ypTNM Classification.
    Mod Pathol. 2026 Jan 22:100963. doi: 10.1016/j.modpat.2026.100963.
    

    >> Share

    
    

    
    N Engl J Med

38. METZGER O, Mandrekar S, Goel S, Gligorov J, et al
    Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.
    N Engl J Med. 2026;394:451-462.
    

    >> Share

    
    

    
    Nature

39. KIM R, Yu J, Lim J, Oh BB, et al
    Whole-genome landscapes of 1,364 breast cancers.
    Nature. 2026;649:1282-1291.
    

    >> Share

    
    

    
    NPJ Breast Cancer

40. YE P, Wen Y, Liu R, Gao W, et al
    Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer.
    NPJ Breast Cancer. 2026 Jan 26. doi: 10.1038/s41523-026-00893.
    

    >> Share

    
    
41. DI GRAZIA G, Sanchez-Bayona R, Casals-Pascual C, Pascual T, et al
    Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology.
    NPJ Breast Cancer. 2026 Jan 28. doi: 10.1038/s41523-026-00904.
    

    >> Share

    
    
42. CABEL L, An JA, Kim HK, Kim J, et al
    Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy.
    NPJ Breast Cancer. 2026 Jan 29. doi: 10.1038/s41523-025-00878.
    

    >> Share

    
    
43. JITWATCHARAKOMOL T, Gokun Y, Walston SA, Obeng-Gyasi S, et al
    The association between local therapies and survival among patients with metastatic inflammatory breast cancer.
    NPJ Breast Cancer. 2026 Jan 29. doi: 10.1038/s41523-026-00899.
    

    >> Share

    
    

    
    Oncogene

44. DHAHRI H, Lau KH, Saintilnord WN, Lopes E, et al
    Single amino-acid differences define H2B variants and modify chromatin accessibility to induce EMT in breast cancer.
    Oncogene. 2026 Jan 24. doi: 10.1038/s41388-025-03636.
    

    >> Share

    
    
45. WU WY, Yang YS, Andriani L, Xie YF, et al
    TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer.
    Oncogene. 2026 Jan 28. doi: 10.1038/s41388-025-03598.
    

    >> Share

    
    

    
    PLoS One

46. MAHAR B, Osman MB, Fauzi FA
    From awareness to action: Health Belief Model-based educational intervention to improve breast self-examination practice among college teachers in Pakistan (CRCT).
    PLoS One. 2026;21:e0341804.
    

    >> Share

    
    
47. YANG C, Li Z, Li G, Mi H, et al
    Exploring the relationship between metabolism and immune microenvironment in breast cancer bone metastasis based on metabolic pathways.
    PLoS One. 2026;21:e0341270.
    

    >> Share

    
    
48. YANG DD, Liu CH, Jia SQ, Xue ZK, et al
    RUBCN as a novel prognostic biomarker and therapeutic target in breast cancer.
    PLoS One. 2026;21:e0341357.
    

    >> Share

    
    
49. HE L, Hu H, Cheng R
    Breast cancer histopathological image classification based on collaborative multi-domain feature learning.
    PLoS One. 2026;21:e0341320.
    

    >> Share

    
    

    
    Radiol Artif Intell

50. GAO Y, Zhou HY, Wang X, Portaluri A, et al
    Visualizing Radiologic Connections: An Explainable Coarse-to-Fine Foundation Model with Multiview Mammograms and Associated Reports.
    Radiol Artif Intell. 2025 Dec 17:e240646. doi: 10.1148/ryai.240646.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share